Welcome to our dedicated page for Seres Therapeutics SEC filings (Ticker: MCRB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Seres Therapeutics, Inc. filings document the disclosure record of a Nasdaq-listed biotechnology company focused on live biotherapeutic and microbiome-based therapeutic programs. Its Form 8-K reports furnish quarterly and annual financial results, operational updates, Regulation FD corporate presentations, and material-event disclosures involving pipeline priorities, clinical and regulatory matters, capital allocation, cost-reduction actions, and financing or partnership activity.
The company’s proxy materials cover annual meeting mechanics, stockholder voting, board governance, executive compensation, and equity-award information. SEC filings also identify Seres’ common stock registered under the Exchange Act and traded on the Nasdaq Global Select Market under the symbol MCRB.
Matthew R. Henn, Chief Scientific Officer and EVP of Seres Therapeutics (MCRB), was granted 3,998 restricted stock units (RSUs) on 09/26/2025. Each RSU converts to one share of common stock and the award was reported as acquired at a $0 price. The RSUs are scheduled to vest in a single installment on 11/15/2025, subject to satisfaction of the award agreement terms, and the RSUs have no expiration date. Following the reported transaction the filing shows beneficial ownership of 3,998 shares reported as direct.
Eric D. Shaff, a director of Seres Therapeutics (MCRB), received and reported the settlement of restricted stock units and a small sale of common stock under a 10b5-1 plan. On 08/15/2025 he had two non-derivative acquisitions: 391 and 333 shares issued on settlement of restricted stock units, increasing his beneficial ownership to 10,493 and 10,826 shares respectively. On 08/18/2025 he sold 217 shares at $16.65 each, which the form states were executed under a Rule 10b5-1 instruction adopted to cover taxes related to RSU vesting. The RSUs vest in scheduled installments (25% earlier vesting followed by quarterly vesting) and have no expiration date.
Insider transactions at Seres Therapeutics (MCRB): Thomas J. DesRosier, a senior executive identified as Chief Legal Officer, EVP, Co‑CEO and Co‑President, reported restricted stock unit vesting and a small sale under a preexisting Rule 10b5‑1 plan. On 08/15/2025 DesRosier had 133 and 111 restricted stock units settle into common shares (total 244 shares) and beneficially owned 7,420 and 7,531 shares respectively after those settlements. On 08/18/2025 he sold 76 shares at $16.65 per share pursuant to the 10b5‑1 instruction to cover taxes related to vesting. The filings state the RSUs vest in scheduled quarterly installments and have no expiration.
Matthew R. Henn, Chief Scientific Officer and EVP of Seres Therapeutics (MCRB), reported equity changes on a Form 4. Restricted stock units vested and settled on 08/15/2025: 141 RSUs and 97 RSUs were reported as acquired/settled, each representing one share. A subsequent sale on 08/18/2025 disposed of 73 shares at $16.65 per share under a Rule 10b5-1 plan adopted April 13, 2023 to cover taxes related to vesting. Following these transactions the filing shows 4,548 shares beneficially owned and remaining RSU balances of 844 and 976 as reported.
Teresa L. Young, EVP, Chief Commercial & Strategy Officer of Seres Therapeutics, Inc. (Ticker: MCRB), reported vesting and settlement of restricted stock units and a small sale of common stock in August 2025. On 08/15/2025 two tranches of restricted stock units were reported (133 and 97 RSUs) that represent contingent rights to receive shares; the filings show post-transaction beneficial ownership figures of 5,177 and 5,274 shares respectively. On 08/18/2025 the reporting person sold 59 shares at $16.65, executed under a Rule 10b5-1 instruction adopted March 5, 2023, described as intended solely to cover taxes relating to RSU vesting. The Form 4 is signed by an attorney-in-fact on 08/19/2025.